Industry News

- Read more about AstraZeneca with Abbott to develop companion diagnostic tests for tralokinumab in severe asthma
AstraZeneca has entered pact with Abbott to develop companion diagnostic tests who are most likely to benefit from the investigational biological therapy, tralokinumab. Till now no companion diagnostic blood tests have been approved for use in asthma.

[adsense:336x280:8701650588]
- Read more about PhoreMost got £1.4 mn fund from Innovate UK
PhoreMost Ltd, a biopharmaceutical company has been selected to receive a funding award of £1.4 mn (approximately $2.14 mn USD) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers. PhoreMost’s lead therapeutic programme has identified drug candidates to a novel synthetic-lethal target for KRAS.
- Read more about Biotronik completes BIOVALVE first-in-human trial for its new transcatheter aortic valve
Biotronik, a leading manufacturer of cardio and endovascular medical devices has completed BIOVALVE first-in-human trial for its new transcatheter aortic valve. Biotronik implanted the device in patients suffering from severe symptomatic aortic stenosis.
- Read more about Dr. Reddy’s Lab launched new drug for stroke patients in India
Dr. Reddy's Laboratories Limited announced the launch of Somazina®, the innovator brand of Citicoline in the Indian market. Dr. Reddy’s has partnered with the global innovator of Citicoline, Ferrer Internacional S.A., Spain, to make Somazina® available in India. This is an important product in the management of stroke and has been used for the treatment of post-stroke patients around the world.
- Read more about US FDA approve breakthrough therapy designation to AbbVie's Venetoclax
AbbVie, a research-based biopharmaceutical company, has been granted breakthrough therapy designation to Venetoclax by the US FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
- Read more about Gujarat introduce India’s first mobile drug testing lab with an investment of Rs. 1 cr
By introducing mobile drug testing lab, making it the first state in the country to possess such a high tech on the go-spot-detecting drug testing laboratory. The state government invest Rs. 1 crore from the funds allocated to the Gujarat Food and Drug Control Administration (FDCA) for this purpose.
18 May 2015

Opto Circuits introduce Powerheart G5 Automated External Defibrillator in US & Canadian markets

Opto Circuits' group company, Cardiac Science, launched newest automated external defibrillator (AED) to the US and Canadian markets. The Powerheart® G5 is the first AED to combine real-time CPR feedback, fully automatic shock delivery, variable escalating energy, and fast shock times.
- Read more about Biocon chairman got 2nd Rank in 'Medicine Maker Power List 2015'
Biocon’s chairman and managing director Kiran Mazumdar-Shaw, got 2nd rank in ‘The Medicine Maker Power List' 2015, an index of the 100 most influential people across the globe in the field of medicine. The top 5 in ‘The Medicine Maker Power List’ are: Anthony Fauci, director, National Institute of Allergy and Infectious Diseases, USA, Kiran Mazumdar-Shaw, chairman & managing director, Biocon, Sir Andrew Witty, chief executive officer, GlaxoSmithKline, Arthur D. Levinson, chief executive officer, Calico and Heather Bresch, chief executive officer of Mylan.
- Read more about US FDA grant Roche's cobas KRAS mutation test for diagnostic use
The US Food and Drug Administration (FDA) has approved Roche's cobas KRAS mutation test for diagnostic use. The real-time PCR test is designed to identify KRAS mutations in tumour samples from metastatic colorectal cancer (mCRC) patients and aid clinicians in determining a therapeutic path for them.
- Read more about Jubilant Life net profit lowered by 56.8% in Q4, dividend at 300%
Jubilant Life Sciences has suffered drop during the fourth quarter ended March 2015 due to lower sales and its consolidated net profit declined sharply by 56.8 per cent to Rs.42.73 crore from Rs.98.81 crore in the corresponding period of last year. Its consolidated net sales also declined by 1.9 per cent to Rs.1,523 crore from Rs.1,552 crore. EBIDTA improved marginally to Rs.253.27 crore from Rs.250.86 crore. EPS declined to Rs.2.68 from Rs.6.20 in the last period. The company management recommended equity dividend of 300 % for the year 2014-15.